Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer

Apatinib is an oral, highly potent tyrosine‐kinase inhibitor targeting VEGFR2. Phase I study showed the recommended dose of 750 mg/day with substantial antitumor activity. This phase II study aims to evaluate the optimum dose level for the efficacy and safety of apatinib monotherapy in heavily pretr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2014-10, Vol.135 (8), p.1961-1969
Hauptverfasser:	Hu, Xichun, Zhang, Jian, Xu, Binghe, Jiang, Zefei, Ragaz, Joseph, Tong, Zhongsheng, Zhang, Qingyuan, Wang, Xiaojia, Feng, Jifeng, Pang, Danmei, Fan, Minhao, Li, Jin, Wang, Biyun, Wang, Zhonghua, Zhang, Qunling, Sun, Si, Liao, Chunmei
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use apatinib Biological and medical sciences Breast cancer Cancer Chemotherapy Disease-Free Survival Drug Resistance, Neoplasm Female Gynecology. Andrology. Obstetrics Humans Kaplan-Meier Estimate Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - secondary Lymphatic Metastasis Mammary gland diseases Medical research Medical sciences Medical treatment Metastasis metastatic breast cancer Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Ovarian cancer Pyridines - pharmacology Pyridines - therapeutic use triple negative Triple Negative Breast Neoplasms - blood Triple Negative Breast Neoplasms - drug therapy Triple Negative Breast Neoplasms - mortality Triple Negative Breast Neoplasms - pathology Tumors Vascular endothelial growth factor Vascular Endothelial Growth Factor A - blood Vascular Endothelial Growth Factor Receptor-2 - antagonists & inhibitors Vascular Endothelial Growth Factor Receptor-2 - blood VEGFR2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!